{"id":1363,"date":"2026-04-12T15:00:00","date_gmt":"2026-04-12T15:00:00","guid":{"rendered":"https:\/\/lotilabs.com\/resources\/?p=1363"},"modified":"2026-09-01T16:09:09","modified_gmt":"2026-09-01T16:09:09","slug":"nad-plus-cellular-energy-longevity-research-guide","status":"publish","type":"post","link":"https:\/\/lotilabs.com\/resources\/nad-plus-cellular-energy-longevity-research-guide\/","title":{"rendered":"NAD+ Research Guide: Cellular Energy, Sirtuin Activation &#038; Longevity Mechanisms"},"content":{"rendered":"<div class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-light-blue ez-toc-container-direction\" id=\"ez-toc-container\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<p><span class=\"ez-toc-title-toggle\"><a aria-label=\"Toggle Table of Content\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" href=\"#\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg class=\"list-377408\" fill=\"none\" height=\"20px\" style=\"fill: #999;color:#999\" viewbox=\"0 0 24 24\" width=\"20px\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg baseprofile=\"tiny\" class=\"arrow-unsorted-368013\" height=\"10px\" style=\"fill: #999;color:#999\" version=\"1.2\" viewbox=\"0 0 24 24\" width=\"10px\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"><\/path><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav>\n<ul class=\"ez-toc-list ez-toc-list-level-1\">\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/lotilabs.com\/resources\/nad-plus-cellular-energy-longevity-research-guide\/#What_Is_NAD\">What Is NAD+?<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/lotilabs.com\/resources\/nad-plus-cellular-energy-longevity-research-guide\/#PARPs_The_NAD_Budget_Problem\">PARPs: The NAD+ Budget Problem<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/lotilabs.com\/resources\/nad-plus-cellular-energy-longevity-research-guide\/#CD38_and_the_Age-Related_NAD_Collapse\">CD38 and the Age-Related NAD+ Collapse<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/lotilabs.com\/resources\/nad-plus-cellular-energy-longevity-research-guide\/#Mitochondria_Cant_Run_Without_It\">Mitochondria Can\u2019t Run Without It<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/lotilabs.com\/resources\/nad-plus-cellular-energy-longevity-research-guide\/#NMN_vs_NR_vs_Direct_NAD\">NMN vs. NR vs. Direct NAD+<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/lotilabs.com\/resources\/nad-plus-cellular-energy-longevity-research-guide\/#Safety_and_Practical_Considerations\">Safety and Practical Considerations<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/lotilabs.com\/resources\/nad-plus-cellular-energy-longevity-research-guide\/#Regulatory_Status\">Regulatory Status<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/lotilabs.com\/resources\/nad-plus-cellular-energy-longevity-research-guide\/#Research_Availability\">Research Availability<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/lotilabs.com\/resources\/nad-plus-cellular-energy-longevity-research-guide\/#Conclusion\">Conclusion<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/lotilabs.com\/resources\/nad-plus-cellular-energy-longevity-research-guide\/#References\">References<\/a><\/li>\n<\/ul>\n<\/nav>\n<\/div>\n<p><em>For laboratory and research use only. Not for human consumption.<\/em><\/p>\n<p>Middle age. Half your NAD+ \u2014 gone. It gets worse. Up to 80% depleted between your twenties and sixty. That\u2019s not a minor biomarker shift. That\u2019s a wholesale biochemical collapse.<\/p>\n<p>NAD+ touches over 500 enzymatic reactions. Burns fuel (glycolysis, TCA cycle, oxidative phosphorylation). And it vanishes with every passing decade.<\/p>\n<p> A lot to cover.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Is_NAD\"><\/span><span class=\"ez-toc-section\" id=\"What_Is_NAD\"><\/span>What Is NAD+?<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Arthur Harden boiled yeast extract in 1906. Something in the filtrate made fermentation go faster. Small molecule. Heat-stable. They called it a \u201ccozymase.\u201d We call it NAD+.<\/p>\n<p>Two nucleotides linked through phosphate groups \u2014 NMN on one side, AMP on the other. Deceptively simple for a molecule that participates in hundreds of reactions.<\/p>\n<ul>\n<li><strong>Molecular Formula:<\/strong> C\u2082\u2081H\u2082\u2087N\u2087O\u2081\u2084P\u2082<\/li>\n<li><strong>Molecular Weight:<\/strong> 663.43 g\/mol<\/li>\n<li><strong>CAS Number:<\/strong> 53-84-9<\/li>\n<\/ul>\n<p>Primary role: electron shuttle. Grabs hydride ions off metabolic substrates in glycolysis, TCA, and oxidative phosphorylation. Becomes NADH. The ratio between NAD\u207a and NADH tells cells what metabolic gear they\u2019re running. High = active oxidation. Low = reduced state (Cant\u00f3 et al., 2015; PMID: 25662603).<\/p>\n<p>But the aging field doesn\u2019t care about the electron shuttle role. It cares about what happens when NAD+ gets <em>consumed<\/em>. Three enzyme families \u2014 sirtuins, PARPs, CD38 \u2014 literally break NAD+ apart. They crack the nicotinamide-ADP-ribose bond and use the fragments for regulatory reactions (Imai &amp; Guarente, 2014; PMID: 24786174).<\/p>\n<p>This is the part people miss. NAD+ isn\u2019t just an electron carrier. It\u2019s expendable fuel for the cell\u2019s highest-priority maintenance systems. And when levels drop with age, those systems starve.<\/p>\n<p>The sirtuin family. SIRT1 through SIRT7. Deacylases that yank acetyl and acyl groups off proteins \u2014 but only when NAD+ is available to power the reaction. Pull NAD+ away and sirtuin activity collapses. That\u2019s not metaphor; it\u2019s enzymology.<\/p>\n<table>\n<thead>\n<tr>\n<th>Sirtuin<\/th>\n<th>Where<\/th>\n<th>What It Does<\/th>\n<th>Standout Data<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>SIRT1<\/td>\n<td>Nucleus\/Cytoplasm<\/td>\n<\/tr>\n<tr>\n<td>SIRT2<\/td>\n<td>Cytoplasm<\/td>\n<td>Cell cycle control<\/td>\n<td>Mitotic checkpoints, adipocyte biology<\/td>\n<\/tr>\n<tr>\n<td>SIRT3<\/td>\n<td>Mitochondria<\/td>\n<td>Mitochondrial deacetylation<\/td>\n<td>Turns on SOD2, respiratory chain. <\/td>\n<\/tr>\n<tr>\n<td>SIRT4<\/td>\n<td>Mitochondria<\/td>\n<td>ADP-ribosylation<\/td>\n<\/tr>\n<tr>\n<td>SIRT5<\/td>\n<td>Mitochondria<\/td>\n<td>Desuccinylation<\/td>\n<td>Urea cycle, fatty acid oxidation<\/td>\n<\/tr>\n<tr>\n<td>SIRT6<\/td>\n<td>Nucleus<\/td>\n<td>Transgenic overexpression \u2192 males lived longer (Kanfi, 2012)<\/td>\n<\/tr>\n<tr>\n<td>SIRT7<\/td>\n<td>Nucleolus<\/td>\n<td>rDNA transcription<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Here\u2019s what makes this family so interesting for aging research. Four entirely different organisms. Not one pathway. A whole web of them \u2014 all gated by NAD+ availability.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"PARPs_The_NAD_Budget_Problem\"><\/span><span class=\"ez-toc-section\" id=\"PARPs_The_NAD_Budget_Problem\"><\/span>PARPs: The NAD+ Budget Problem<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>PARP1 and PARP2 do 90% of PARP activity in mammalian cells. Crucial work. But incredibly expensive \u2014 measured in NAD+ molecules consumed.<\/p>\n<p>Acute DNA damage can trigger PARP hyperactivation. When that happens? NAD+ reserves get torched. Rapidly. And every NAD+ molecule PARP burns is one the sirtuins can\u2019t use.<\/p>\n<p>Proof: PARP1 knockout mice. No PARP1 means no NAD+ drain from DNA repair. Chemical PARP inhibitors did the same thing. Block one NAD+ consumer, and the others feast.<\/p>\n<p>This is the fundamental tension in NAD+ biology. PARPs, CD38, and sirtuins all compete for a limited NAD+ supply. A zero-sum game at the molecular level. Understanding who\u2019s winning that competition at any given point in the aging process \u2014 that\u2019s what drives the entire NAD+ repletion field (Mouchiroud et al., 2013; PMID: 23698361).<\/p>\n<h2><span class=\"ez-toc-section\" id=\"CD38_and_the_Age-Related_NAD_Collapse\"><\/span><span class=\"ez-toc-section\" id=\"CD38_and_the_Age-Related_NAD_Collapse\"><\/span>CD38 and the Age-Related NAD+ Collapse<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>CD38. Ectoenzyme. Chews through NAD+ and spits out cyclic ADP-ribose for calcium signaling. And its expression climbs \u2014 relentlessly \u2014 as organisms age. If you want a single culprit for age-related NAD+ loss, this is it.<\/p>\n<p>The decline in numbers:<\/p>\n<ul>\n<li>~50% of NAD+ gone by middle age (Yoshino et al., 2018; PMID: 29514064)<\/li>\n<li>Skin by 60: 50\u201380% depleted (Massudi et al., 2012; PMID: 22848760)<\/li>\n<li>Brain loses 10\u201325%. Liver about 30% (over-60 vs. under-45)<\/li>\n<li>Men drop faster, especially mid-life<\/li>\n<\/ul>\n<p>Knockout experiment: remove CD38 entirely from mice. NAD+ stays elevated. SIRT1 cranks up. High-fat-diet metabolic damage? Protected (Barbosa et al., 2007; PMID: 17376880).<\/p>\n<p>Why does CD38 increase with age? Blame inflammaging. Chronic low-grade inflammation. Fewer NAD+ molecules \u2192 more senescent cells \u2192 more inflammatory cytokines \u2192 higher CD38 expression \u2192 even less NAD+. A self-reinforcing spiral that accelerates with every year.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Mitochondria_Cant_Run_Without_It\"><\/span><span class=\"ez-toc-section\" id=\"Mitochondria_Cant_Run_Without_It\"><\/span>Mitochondria Can\u2019t Run Without It<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every time the TCA cycle turns, it produces NADH. That NADH hands electrons to Complex I \u2014 the biggest, first complex in the electron transport chain. Kill that handoff and ATP production collapses. No NAD+ recycling, no energy. Full stop.<\/p>\n<p>Three specific connections:<\/p>\n<p>When Complex I is deficient, NADH piles up because it can\u2019t pass electrons forward. Mitochondrial NAD+ crashes. SIRT3 goes dark. Tissue damage follows. <\/p>\n<p>SIRT3 itself deacetylates subunits in both Complex I and Complex II. It\u2019s the quality control enzyme for the respiratory chain. And it runs on NAD+. Low NAD+ means sloppy mitochondria.<\/p>\n<p>Then there\u2019s biogenesis \u2014 making entirely new mitochondria. SIRT1 deacetylates PGC-1\u03b1, which kicks off mitochondrial production. SIRT1 needs NAD+. So NAD+ levels control not just how well existing mitochondria work but how many new ones get built.<\/p>\n<p>+.<\/p>\n<p>Here\u2019s where NAD+ goes from interesting chemistry to \u201cmaybe we can reverse aging.\u201d<\/p>\n<h3>Worms<\/h3>\n<p>Give <em>C. elegans<\/em> NAD+ precursors and block PARPs. The worm sirtuin (sir-2.1) fires up. Mitochondria work better. The worms live longer. Simple experiment, clear result: busted NAD+ metabolism <em>causes<\/em> aging phenotypes. It\u2019s not just correlated \u2014 fix the NAD+ and you fix the decline (Mouchiroud et al., 2013; PMID: 23698361).<\/p>\n<h3>Old Mice<\/h3>\n<p>Late-middle-age mice. NMN dissolved in drinking water at 500 mg\/kg\/day. Lipid profiles cleaned up. Mitochondria hummed again. The animals moved more. Organ after organ reversed its age-related slide. <\/p>\n<h3>One Gene, Longer Life<\/h3>\n<p>Extra SIRT6 copies? Male mice lived longer. Lower IGF-1. Just one sirtuin gene (Kanfi et al., 2012; PMID: 22367546). Target SIRT1 to the hypothalamus? Both sexes lived longer. <\/p>\n<h2><span class=\"ez-toc-section\" id=\"NMN_vs_NR_vs_Direct_NAD\"><\/span><span class=\"ez-toc-section\" id=\"NMN_vs_NR_vs_Direct_NAD\"><\/span>NMN vs. NR vs. Direct NAD+<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The precursor question. Three molecules, three routes to the same destination.<\/p>\n<table>\n<thead>\n<tr>\n<th><\/th>\n<th>NMN<\/th>\n<th>NR<\/th>\n<th>Direct NAD+<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>MW<\/strong><\/td>\n<td>334 g\/mol<\/td>\n<td>255 g\/mol<\/td>\n<td>663 g\/mol<\/td>\n<\/tr>\n<tr>\n<td><strong>Conversion Steps<\/strong><\/td>\n<td>One (NMNAT)<\/td>\n<td>Two (NRK \u2192 NMNAT)<\/td>\n<td>Zero. Already NAD+<\/td>\n<\/tr>\n<tr>\n<td><strong>Oral Route<\/strong><\/td>\n<td>Fast absorption, salvage pathway<\/td>\n<td>Phosphorylated before conversion<\/td>\n<td>Big molecule \u2014 parenteral routes studied<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Straightforward, right? Fewer steps should mean faster NAD+ elevation. Except a 2025 <em>Science Advances<\/em> paper complicated the picture. Both NMN and NR, when taken orally, get mostly broken down to plain nicotinamide (NAM) in the gut and liver first. Then re-synthesized into NAD+ through the Preiss-Handler pathway. The precursors themselves spiked in blood within 15 minutes \u2014 gone by 60. Actual NAD+ elevation was slower and more sustained (Yaku et al., 2025; DOI: 10.1126\/sciadv.adr1538).<\/p>\n<p>So much for the \u201cdirect conversion\u201d narrative. The body routes things its own way.<\/p>\n<p>Direct <a href=\"https:\/\/lotilabs.com\/product\/nad-500mg\/\">NAD+ 500mg<\/a> administration bypasses all of that. It <em>is<\/em> the finished molecule. No enzymatic middlemen. The catch: 663 Da is nearly double the size of NMN, which complicates absorption. Parenteral delivery solves that, oral delivery doesn\u2019t. Pick your trade-off based on protocol needs.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Safety_and_Practical_Considerations\"><\/span><span class=\"ez-toc-section\" id=\"Safety_and_Practical_Considerations\"><\/span>Safety and Practical Considerations<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Generally favorable safety profile across preclinical models. NMN at 100\u2013500 mg\/kg\/day in mice showed no significant adverse findings in long-term studies (Mills et al., 2016).<\/p>\n<p>Watch for:<\/p>\n<ul>\n<li>NAD\u207a\/NADH ratio matters for protocol design. The oxidized-to-reduced balance influences multiple pathways simultaneously. Don\u2019t ignore it<\/li>\n<li>NAD+ degrades with light, heat, and pH extremes. Store properly or your measurements are artifacts<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Regulatory_Status\"><\/span><span class=\"ez-toc-section\" id=\"Regulatory_Status\"><\/span>Regulatory Status<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>NAD+ is a research compound available for laboratory and investigational use. Not FDA-approved as a standalone agent. NAD+ and its precursors (NMN, NR) are available through research suppliers for preclinical work.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Research_Availability\"><\/span><span class=\"ez-toc-section\" id=\"Research_Availability\"><\/span>Research Availability<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>From Loti Labs:<\/p>\n<ul>\n<li><a href=\"https:\/\/lotilabs.com\/product\/nad-500mg\/\">NAD+ 500mg<\/a> \u2014 $99.99<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>NAD+ vanishes as we age. CD38 drives the loss. Sirtuins and PARPs fight over what remains. Mitochondria stall. <\/p>\n<p>But give aging animals NAD+ back? Mitochondria fire up. Physical function returns. That\u2019s the preclinical promise \u2014 and it\u2019s consistent across worms, mice, and every model organism tested so far.<\/p>\n<p>Open questions remain. Delivery optimization. Tissue-specific kinetics. How much PARP capacity do you sacrifice for sirtuin gains? What\u2019s the circadian angle? Big questions. But NAD+ left the \u201cspeculative\u201d category years ago. This is bedrock aging biology now.<\/p>\n<p><em>For laboratory and research use only. Not for human consumption.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"References\"><\/span><span class=\"ez-toc-section\" id=\"References\"><\/span>References<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ol>\n<li>Imai S, Guarente L. NAD+ and sirtuins in aging and disease. <em>Trends Cell Biol.<\/em> 2014;24(8):464-471. PMID: 24786174<\/li>\n<li>Cant\u00f3 C, Menzies KJ, Auwerx J. <em>Cell Metab.<\/em> 2015;22(1):31-53. PMID: 26118927<\/li>\n<li>Mouchiroud L, Houtkooper RH, Moullan N, et al. <em>Cell.<\/em> 2013;154(2):430-441. PMID: 23698361<\/li>\n<li>Mills KF, Yoshida S, Stein LR, et al. Long-term NMN administration mitigates age-associated physiological decline in mice. <em>Cell Metab.<\/em> 2016;24(6):795-806. PMID: 28068222<\/li>\n<li>Kanfi Y, Naiman S, Amir G, et al. <em>Nature.<\/em> 2012;483(7388):218-221. PMID: 22367546<\/li>\n<li>Satoh A, Brace CS, Rensing N, et al. Sirt1 extends life span and delays aging in mice through DMH and LH regulation. <em>Cell Metab.<\/em> 2013;18(3):416-430. PMID: 23746838<\/li>\n<li>Bai P, Cant\u00f3 C, Oudart H, et al. <em>Cell Metab.<\/em> 2011;13(4):461-468. PMID: 21459330<\/li>\n<li>Barbosa MT, Soares SM, Novak CM, et al. CD38 is a key regulator of diet-induced body weight gain. <em>Biochem J.<\/em> 2007;403(Pt 3):573-581. PMID: 17376880<\/li>\n<li>Gibson BA, Kraus WL. New insights into poly(ADP-ribose) and PARPs. <em>Nat Rev Mol Cell Biol.<\/em> 2012;13(7):411-424. PMID: 22713970<\/li>\n<li>Yoshino J, Baur JA, Imai S. <em>Cell Metab.<\/em> 2018;27(3):513-528. PMID: 29514064<\/li>\n<li>Massudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. <em>PLoS One.<\/em> 2012;7(7):e42357. PMID: 22848760<\/li>\n<li>Karamanlidis G, Lee CF, Garcia-Menendez L, et al. Complex I deficiency increases protein acetylation and accelerates heart failure. <em>Cell Metab.<\/em> 2013;18(2):239-250. PMID: 23931755<\/li>\n<li>Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. <em>Annu Rev Pathol.<\/em> 2010;5:253-295. PMID: 20078221<\/li>\n<li>Yaku K, et al. NR and NMN facilitate NAD+ synthesis via enterohepatic circulation. <em>Sci Adv.<\/em> 2025. DOI: 10.1126\/sciadv.adr1538<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Comprehensive NAD+ research guide covering the coenzyme&#8217;s role in 500+ enzymatic reactions, age-related decline, sirtuin activation, mitochondrial function, and precursor compound comparisons.<\/p>\n","protected":false},"author":1,"featured_media":1387,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-1363","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peptides"],"_links":{"self":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1363","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/comments?post=1363"}],"version-history":[{"count":0,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1363\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media\/1387"}],"wp:attachment":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media?parent=1363"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/categories?post=1363"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/tags?post=1363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}